Allergic reactions to the Ad26.COV2.S vaccine in South Africa.

ABSTRACT:

Background

The Janssen-Ad26.COV2.S vaccine is authorized for use in several countries, with more than 30 million doses administered. Mild and severe allergic adverse events following immunization (AEFI) have been reported.

Objective

We sought to detail allergic reactions reported during the Sisonke phase 3B study in South Africa.

Methods

A single dose of the Ad26.COV2.S vaccine was administered to 4,77,234 South African health care workers between February 17 and May 17, 2021. Monitoring of adverse events used a combination of passive reporting and active case finding. Telephonic contact was attempted for all adverse events reported as "allergy." Anaphylaxis adjudication was performed using the Brighton Collaboration and National Institute of Allergy and Infectious Di

SUBMITTER: Peter J 

PROVIDER: S-EPMC10509997 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature